The short answer
Kava may add to lemborexant-related drowsiness and next-day impairment. Review co-use before adding it, especially when the supplement is being used as another sleep aid.
What this answer covers
Piper methysticum oral beverages and extracts; plant part and preparation matter.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- lemborexant
Why alertness matters
Lemborexant can impair alertness and next-day activities. Its label warns about additive effects with other central nervous system depressants. That precaution does not provide an adverse-event rate for this supplement combination.
What is known about this product
Supplement-specific evidence describes drowsiness or cautions about sedative co-use. The inspected sources do not establish the risk or benefit of this exact combination.
A metabolic interaction has not been demonstrated
A human kava study found no significant change in oral midazolam pharmacokinetics after the tested preparation. That indirect result challenges a blanket claim that kava changes CYP3A-substrate exposure, but it does not rule out additive drowsiness with lemborexant. No exact-pair absorption or sleep-benefit change was established.
Plan co-use with the prescriber
Discuss the exact product and other sleep medicines before adding it. A short spacing interval has not been shown to prevent additive impairment. Do not drive while impaired. If sleepwalking, sleep-driving or other activities while not fully awake occur, stop lemborexant and contact the prescriber promptly, as its label instructs.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-sedation and co-use review precaution from exact medication labeling and supplement evidence. No measured pair incidence or protective timing interval; no claim of a universal botanical contraindication.
- Exact scope
- Piper methysticum oral beverages and extracts; plant part and preparation matter. with Lemborexant2272403 IN, oral DAYVIGO tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed lemborexant
Avoid strong/moderate CYP3A inhibitors and inducers; St John’s wort explicitly named. Other insomnia medicines not recommended. Additive CNS depression and complex sleep behaviors.
How this applies: Exact lemborexant RxCUI 2272403 IN, with stated salt/formulation/route bridge.
No measured seed-extract, CBD, kava or generic valerian combination risk.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for lemborexant only within the stated preparation and endpoint limits.
Not a direct lemborexant combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for lemborexant only within the stated preparation and endpoint limits.
Four-week kava/valerian insomnia/anxiety efficacy trial; failure to show benefit is not proof of absent sedation. No lemborexant combination.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 healthy adults.
Goldenseal increased midazolam exposure; kava produced no significant effect on midazolam disposition.
How this applies: Original source interpreted for lemborexant only within the stated preparation and endpoint limits.
Exact kava preparation for14days did not change oral midazolam PK. Indirect CYP3A probe result, not a lemborexant absorption, efficacy or combined-sedation study.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy adults in phase1 open-label studies.
Inhibitors increased exposure approximately3.7–4fold; rifampin reduced exposure over90%. No severe or serious adverse events reported.
How this applies: Other drugs, not supplements. Expected somnolence15minutes–9hours was not recorded as an adverse event unless more pronounced than expected. Lemborexant’s null effect on midazolam is the reverse interaction direction.
Other drugs, not supplements. Expected somnolence15minutes–9hours was not recorded as an adverse event unless more pronounced than expected. Lemborexant’s null effect on midazolam is the reverse interaction direction.
Research assessment: · Open full citations ↗
Absorption & effectiveness
No exact kava-lemborexant absorption or effectiveness result. Human midazolam probe PK was unchanged with tested kava; general sedation does not establish altered exposure or therapeutic effectiveness.
- Exact scope
- Piper methysticum oral beverages and extracts; plant part and preparation matter. with Lemborexant2272403 IN, oral DAYVIGO tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed lemborexant
Avoid strong/moderate CYP3A inhibitors and inducers; St John’s wort explicitly named. Other insomnia medicines not recommended. Additive CNS depression and complex sleep behaviors.
How this applies: Exact lemborexant RxCUI 2272403 IN, with stated salt/formulation/route bridge.
No measured seed-extract, CBD, kava or generic valerian combination risk.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for lemborexant only within the stated preparation and endpoint limits.
Not a direct lemborexant combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for lemborexant only within the stated preparation and endpoint limits.
Four-week kava/valerian insomnia/anxiety efficacy trial; failure to show benefit is not proof of absent sedation. No lemborexant combination.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 healthy adults.
Goldenseal increased midazolam exposure; kava produced no significant effect on midazolam disposition.
How this applies: Original source interpreted for lemborexant only within the stated preparation and endpoint limits.
Exact kava preparation for14days did not change oral midazolam PK. Indirect CYP3A probe result, not a lemborexant absorption, efficacy or combined-sedation study.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy adults in phase1 open-label studies.
Inhibitors increased exposure approximately3.7–4fold; rifampin reduced exposure over90%. No severe or serious adverse events reported.
How this applies: Other drugs, not supplements. Expected somnolence15minutes–9hours was not recorded as an adverse event unless more pronounced than expected. Lemborexant’s null effect on midazolam is the reverse interaction direction.
Other drugs, not supplements. Expected somnolence15minutes–9hours was not recorded as an adverse event unless more pronounced than expected. Lemborexant’s null effect on midazolam is the reverse interaction direction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact lemborexant article with formulation-specific evidence and uncertainty. |
Article revision: 8792109983d182e0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.